2020

1. Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

   Breast, Vol. 54, pp. 286-292

2. Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study)

   Breast Cancer Research and Treatment, Vol. 184, Núm. 2, pp. 469-479